Could Moderna's mRNA Magic Revive Its Beaten-Down Biotech Partner?
The past year has been bumpy for Vertex Pharmaceuticals (NASDAQ: VRTX). I'm not talking about earnings. The company has consistently generated billions of dollars in revenue from its cystic fibrosis (CF) drugs.
The most recent quarter was no exception. Vertex's product revenue climbed 29% to nearly $2 billion. And the company raised its full-year revenue forecast to at least $7.4 billion.
So how is Vertex suffering? The stock has slumped about 30% over the past year after two non-CF candidates failed during clinical trials.
Source Fool.com
